YaoGeJu

Company directoryChina company filings

Chengdu Shengnuo Biopharm Co.,Ltd.

As of 18 November 2026, for the company name Chengdu Shengnuo Biopharm Co.,Ltd. as recorded, the chemical-drug catalogue lists 13 active records with this name as holder; 27 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

18 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Octreotide Acetate Injection 2 records · Latest accepted 2026/04/16

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2600762Supplement2026/04/16Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHB2150703Supplement2021/07/05Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
特立帕肽注射液 · No verified English name 1 records · Latest accepted 2025/07/30

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHL2500773New drug2025/07/30Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Exenatide Injection 3 records · Latest accepted 2025/02/18

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500772Generic2025/02/18Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHS2402713Generic2024/08/20Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHS2200215Generic2022/01/28Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Terlipressin Acetate Injection 1 records · Latest accepted 2024/11/23

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404027Generic2024/11/23Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Linaclotide Capsules 1 records · Latest accepted 2024/11/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403816Generic2024/11/08Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
泊沙康唑注射液 · No verified English name 2 records · Latest accepted 2024/07/25

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2401109Supplement2024/07/25Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHS2201278Generic2022/08/10Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Ganirelix Injection 1 records · Latest accepted 2024/01/23

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400298Generic2024/01/23Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Carbetocin Injection 2 records · Latest accepted 2023/11/22

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2302571Supplement2023/11/22Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHB2250260Supplement2022/05/05Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Levosimendan Injection 1 records · Latest accepted 2023/02/01

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2350115Supplement2023/02/01Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Thymalfasin for Injection 1 records · Latest accepted 2021/11/17

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2150996Supplement2021/11/17Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Atosiban Acetate Injection 2 records · Latest accepted 2021/07/12

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2150730Supplement2021/07/12Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
CYHB2150729Supplement2021/07/12Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗
Somatostatin For Injection 1 records · Latest accepted 2021/05/12

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2150574Supplement2021/05/12Chengdu Shengnuo Biopharm Co.,Ltd.CDE ↗

Changes in the last 90 days

2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

No longer listed under review: 1 applicationSupplement delivery: 1 application

  1. 2026/11/12No longer listed under review

    Octreotide Acetate Injection

    CYHB2600762

    Fact date: 2026/11/12 · Date added to this site: 2026/11/12

    Accepted: 2026/04/16

    no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20269267; approval date: 2026/11/10); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 31

    NMPA · Table row 31 ↗ View source ↗
  2. 2026/11/10Supplement delivery

    Octreotide Acetate Injection

    CYHB2600762 · 国药准字H20269267

    Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14

    Supplemental application; excluded from new marketing approvals.

    View source · Table row 31 ↗

Under review

0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Catalogue holder records

13 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Linaclotide CapsulesChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202657742026/09/02Generic approved under the new chemical-drug registration classificationCDE ↗
Exenatide InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202562372025/12/09Generic approved under the new chemical-drug registration classificationCDE ↗
Ganirelix InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202548732025/07/15Generic approved under the new chemical-drug registration classificationCDE ↗
Exenatide InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202546052025/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
泊沙康唑注射液 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202435792024/04/24Generic approved under the new chemical-drug registration classificationCDE ↗
Levosimendan InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201101042024/02/18Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Carbetocin InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201630012023/08/31Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Thymalfasin for InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201431122023/01/11Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Atosiban Acetate InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201840942022/08/31Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Atosiban Acetate InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201732562022/08/31Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Octreotide Acetate InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201531592022/07/07Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Somatostatin For InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H201832492022/07/05Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Eptifibatide InjectionChengdu Shengnuo Biopharm Co.,Ltd.Chengdu Shengnuo Biopharm Co.,Ltd.国药准字H202036462020/12/08Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

27 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
鲑降钙素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20250001368I2025/12/25CDE ↗
醋酸去氨加压素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20250000948I2025/09/17CDE ↗
培来加南 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20240001346A2026/06/25CDE ↗
缩宫素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20240001217A2026/06/04CDE ↗
醋酸特利加压素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20240000973A2026/08/28CDE ↗
利那洛肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20240000089A2026/03/02CDE ↗
维培那肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20230000631A2025/12/18CDE ↗
醋酸艾替班特 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20220001345A2024/10/11CDE ↗
醋酸西曲瑞克 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20220000342A2024/02/23CDE ↗
泊沙康唑 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20220000311A2024/03/19CDE ↗
醋酸加尼瑞克 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20210000010A2022/11/04CDE ↗
利那洛肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20200001056I2020/11/06CDE ↗
枸橼酸倍维巴肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190021501A2024/07/03CDE ↗
特立帕肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20200000763I2020/07/23CDE ↗
醋酸奥曲肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190007931A2025/07/04CDE ↗
恩夫韦肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190007396A—CDE ↗
生长抑素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190007382A2024/01/17CDE ↗
胸腺法新 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190007213A2024/11/29CDE ↗
醋酸阿托西班 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190006802A2026/08/08CDE ↗
胸腺五肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190006694A2023/03/24CDE ↗
左西孟旦 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190006426A2026/05/11CDE ↗
卡贝缩宫素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20190005921A2025/09/16CDE ↗
利拉鲁肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20180001759I—CDE ↗
比伐芦定 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20170002315A2026/04/16CDE ↗
依替巴肽 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20170001653A2025/09/16CDE ↗
醋酸特利加压素 · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20170001257I—CDE ↗
艾塞那肽等29个品种(详见品种信息表) · No verified English nameChengdu Shengnuo Biopharm Co.,Ltd.Y20170000554A2025/11/01CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.